MedTrace Logo

Terahertz Metamaterials for Tumour Marker Concentration Identification

NCT04125524 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2023-11-01

No results posted yet for this study

Summary

The research the investigators plan to undertake involves the use of a metamaterial at terahertz frequencies. Serum samples will be tested using the metamaterial to determine if this method can be used to measure the concentration of tumour markers present in the sample. Patients who have been tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP will be used for both the positive and negative samples.

Conditions

  • Malignant Tumour

Interventions

DIAGNOSTIC_TEST

Terahertz metamaterials

A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.

Sponsors & Collaborators

  • County Durham and Darlington NHS Foundation Trust

    collaborator OTHER_GOV

  • Durham University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-17
Primary Completion
2022-10-01
Completion
2025-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04125524 on ClinicalTrials.gov